Modified cytokines for use in cancer therapy

Details Modified cytokines for use in cancer therapy Modified cytokines for use in cancer therapy

2006-01-25

2009-11-24

Gamett, Daniel C (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

C424S085500, C424S185100, C514S002600, C514S012200, C514S009100, C514S016700, C514S017400

Reexamination Certificate

active

07622105

ABSTRACT:
Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.

REFERENCES:
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4791101 (1988-12-01), Adolf
patent: 5258517 (1993-11-01), Zepp et al.
patent: 5539063 (1996-07-01), Hakimi et al.
patent: 5811388 (1998-09-01), Friend et al.
patent: 5888814 (1999-03-01), Kriegler et al.
patent: 6180084 (2001-01-01), Ruoslahti et al.
patent: 6576239 (2003-06-01), Ruoslahti et al.
patent: 6759509 (2004-07-01), King et al.
patent: 0 251 494 (1988-01-01), None
patent: 0 496 074 (1992-07-01), None
patent: WO 95/15979 (1995-06-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 99/13329 (1999-03-01), None
patent: WO 01/61017 (2001-08-01), None
Lohn et al. (Leuk. Lymphoma, 2002, 43(2):407-413).
Tabata et al., “Targeting of Tumor Necrosis Factor to Tumor by Use of Dextran and Metal Coordination,”Journal of Controlled Release 59, 1999, pp. 187-196.
Miyata et al., “Overcoming the Metastasis-Enhancing Potential of Human Tumor Necrosis Factor α by Introducing the Cell-Adhesive Arg-Gly-Asp Sequence,” 1995, pp. 161-169.
Hottiger, Mo, et al., “Liposome-mediated gene transfer into human basal cell carcinoma”,Gene Therapy, 1999, 6:1929-1935.
Flavio Curnis, et al., “Enhancement Of Tumor Necrosis Factor α Antitumor Immunotherapeutic Properties By Targeted Delivery To Aminopeptidase N(CD13)”, Nature Biotechnology vol. 18, Nov. 2000, pp. 1185-1190.
Helson, et al., Effect of Tumor Necrosis Factor on Cultured Human Melanoma Cells,Nature1975, 258, pp. 731-732.
Schraffordt et al., Hyperthermic Isolated Limb Perfusion with Tumour Necrosis Factor and Melphalan as Treatment of Locally Advanced or Recurrent Soft Tissue Sarcomas of the Extremities, Radiotherapy & Oncology 1998, 48: pp. 1-4.
Pennica, et al., “Cloning and expression inEscherichia coliof the cDNA for murine tumor necrosis factor,”Proc. Natl. Acad. Sci. USA, 82:6060-6064 (1985), USA.
Ostade, et al., “Human TNF mutants with selective activity on the p55 receptor,”Nature, 361:266-269 (1993), Belgium.
Koops, et al., “Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities,”Radiotherapy and Oncology, 48:1-4 (1998), Elsevier Science Ireland Ltd., UK.
Arap, et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model,”Science, 279:377-381 (1998), USA.
Liénard, et al., “In Transit Metastases of Malignant Melanoma Treated by High Dose rTNFα in Combination with Interferon-γ and Melphalan in Isolation Perfusion,”World J. Surg., 16:234-240 (1992), Societe Internationale de Chirurgie, Belgium.
Corti, et al., “Upregulation of p75 Tumor Necrosis Factor Alpha Receptor inMycobacterium avium-Infected Mice: Evidence for a Functional Role,”Infection and Immunity, 67(11):5762-5767 (1999), American Society for Microbiology.
Loetscher, et al., “Human Tumor Necrosis Factor α (TNFα) Mutants with Exclusive Specificity for the 55-kDa or 75-kDa TNF Receptors,”The Journal of Biological Chemistry, 268(35):26350-26357 (1993), The American Society for Biochemistry and Molecular Biology, Inc., USA.
Colombo, et al., “Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine
euroendocrine tumors,”J. Endocrinol. Invest., 16:841-843 (1993), Germany.
Ljunggren, et al., “Host Resistance Directed Selectively Against H-2-Deficient Lymphoma Variants,”J. Exp. Med., 162:1745-1759 (1985), The Rockefeller University Press, USA.
Corti, et al., “Tumor necrosis factor (TNF) α quantification by Elisa and bioassay: effects of TNFα-soluble TNF receptor (p55) complex dissociation during assay incubations,”Journal of Immunological Methods, 177:191-198 (1994), Elsevier Science B.V., UK.
Palladino, et al., “Characterization of the Antitumor Activities of Human Tumor Necrosis Factor-α and the Comparison with Other Cytokines: Induction of Tumor-Specific Immunity,”The Journal of Immunology, 138(11):4023-4032 (1987), The American Association of Immunologists, USA.
Debs, et al., “Immunomodulatory and Toxic Effects of Free and Liposome-encapsulated Tumor Necrosis Factor α in Rats,”Cancer Research, 50:375-380 (1990), USA.
Moro, et al., “Tumor Cell Targeting with Antibody-Avidin Complexes and Biotinylated Tumor Necrosis Factor α,”Cancer Research, 57:1922-1928 (1997), Italy.
Robert, et al., “Cytokine Targeting in Tumors Using a Bispecific Antibody Directed against Carcinoembryonic Antigen and Tumor Necrosis Factor α,”Cancer Research, 56:4758-4765 (1996).
Debs, et al., “Liposome-Associated Tumor Necrosis Factor Retains Bioactivity in the Presence of Neutralizing Anti-Tumor Necrosis Factor Antibodies,”The Journal of Immunology, 143(4), 1192-1197 (1989), The American Association of Immunologists, USA.
Hoogenboom, et al., “Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins,”Molecular Immunology, 28(9):1027-1037 (1991), Pergamon Press, UK.
Yang, et al., “A Genetically Engineered Single-Chain FV/TNF Molecule Possesses the Anti-Tumor Immunoreactivity of FV as well as the Cytotoxic Activity of Tumor Necrosis Factor,”Mol. Immunol., 1995, 32:873-881, Elsevier Science Ltd., UK.
Eggermont, et al., “Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas,”Annals of Surgery, 224(6):756-765 (1996), Lippincott-Raven Publishers.
Rathjen, et al., “Selective enhancement of the tumour necrotic activity of TNF, with monoclonal antibody,”Br. J. Cancer, 65:857-864 (1992), Macmillan Press Ltd., USA.
Modorati, et al., Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results,British Journal of Ophthalmol., 78:19-23 (1994), UK.
Hill, et al., Low-does tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion,British J. Surg., 80:995-997 (1993), Butterworth-Heinemann Ltd, UK.
Paganelli, et al., “Three-Step Monoclonal Antibody Tumor Targeting in Carcinoembryonic Antigen-Positive Patients,”Cancer Research, 51:5960-5966 (1991).
Paganelli, et al., “Clinical Application of the Avidin-Biotin System for Tumor Targeting,”Can. Therapy with Radiolabelled Antibodies, 239-254 (1995), CRC Press, Inc., UK.
Gasparri, et al., “Tumor Pretargeting with Avidin Improves the Therapeutic Index of Biotinylated Tumor Necrosis Factor α in Mouse Models,”Cancer Research, 59:2917-2923 (1999).
Mizuguchi, et al., “Tumor Necrosis Factor α-mediated Tumor Regression by the in vivo Transfer of Genes into the Artery That Leads to Tumors,”Cancer Research, 58:5725-5730 (1998).
Corti, et al., “Tumor Targeting with Biotinylated Tumor Necrosis Factor α: Structure-Activity Relationships and Mechanism of Action on Avidin Pretargeted Tumor Cells,”Cancer Research, 58:3866-3872 (1998).
Fiers, “Chapter 12 Biologic Therapy with TNF: Preclinical Studies,”Biologic Therapy of Cancer: Principles and Practice, 1995, pp. 295-327, JB Lippincott Company, Phila., PA.
Fraker, et al., “Chapter 13 Biologic Therapy with TNF: Systemic Administration and Isolation-Perfusion,”Biologic Therapy of Cancer: Principles and Practice, 1995, pp. 329-345, JB Lippincott Company, Phila., PA.
Pasqualini, et al., “Aminopeptidase N Is a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis,”Cancer Research, 60:722-727, (2000).
Chen, et al., “Enhanced Anti-tumor Effect of an IFN-γ-EGF Fusion Protein,”Biomedical and Environmental Sciences, 10:387-395 (199

Affiliated with

Also associated with

Rating

Modified cytokines for use in cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified cytokines for use in cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified cytokines for use in cancer therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4078300